Very excited to be presenting my research on the incidence of AKI with AUC dosing of vancomycin in the outpatient setting at IDWeek! #IDWeek2021 https://t.co/Pf8a22plIb
Phase 1 of the Cefazolin for All revolution is complete.
We (@KimberlyBlumen1, Bernardo Sousa-Pinto, Lindsay Courtney, Christian Mancini) did a SR and MA of an absolute BOAT LOAD of articles to measure the rate of dual allergy between cefazolin and penicillins.
Our findings...
🔥Cohort🔥
Oral β-lactam antibiotics are a reasonable step-down alternative to TMP-SMX or FQs after a median 5 days of IV antibiotics in adults w Enterobacterales bacteremia from a suspected urinary source
Kinda long duration 14 d 🤔
H/t @IDPharmacometrx https://t.co/SuPW2cubAy
NEW 🔥🔥 #AAC
CSF penetration of ceftolozane/tazobactam in critically ill pts w an indwelling EVD
The current maximal dose of C/T (3.0 g 8-hourly) does NOT provide adequate CSF exposure for treatment of G- meningitis or ventriculitis unless MIC ≤0.25
https://t.co/LGlYKVz4GN
Remdesivir FAILED in the large Solidarity trial, expectedly on mortality, but more surprisingly on the time to recovery.
Would Remdesivir still be considered the standard of care ?!
NIH guidelines👇
NEW 🔥🔥🔥@JAMA_current
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society–USA Panel. #IDTwitter https://t.co/JMkl3qhAFR
🚨🗓️Please join us for the first ID PRN Learner-Led Journal Club on September 18th at 12PM Central Time! 🤓 Journal articles and other details below! Zoom passcode can be found via email on the ID PRN Listserv.
Congratulations @pranita_tamma @OncIDPharmd@davidvanduin@ClancyNeil and #twitterless Drs. Mathers and Bonomo on publishing the @IDSAInfo Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections!!
https://t.co/SAsO0mjee9
A new prospective cohort study in #CMI
🕟💉🤒🎯
Administration of antibiotics within 4 hours of admission had NO significant effect on the outcomes in patients with CAP.
#IDTwitter https://t.co/y3bNMr11g7
Systematic review by @LDanielsPharmD on ASP interventions for discharge prescribing. Antibiotic prescribing at hospital discharge is a priority often not addressed by ASPs. More studies needed. #Systematicreview Full article available here: https://t.co/W7xgYnUuIR
TOL-TAZ resistance has been reported. A small study #CID @pranita_tamma @SimnerLab
sought to identify modifiable risk factors that may reduce the emergence of TOL-TAZ resistance.#IDTwitter
https://t.co/J8M3N2uPK1
🔥🔥This prospective meta-analysis of 7 RCTs that included 1703 critically ill patients with #COVID19 recruited from countries on 5 continents, administration of corticosteroids was associated with lower all-cause mortality at 28 days after randomization🔥🔥 Thanks @JAMA_current
Decided to pick the brain of a few ID friends today to see which articles they might use to prepare a PGY1 resident for an Antibiotic Resistance Discussion...here are a few good ones to share with #IDTwitter too (1/n)
Which article(s) do you you like to use? 🤔
🌟β-lactam Dosing Strategies: Think before You Push.🌟
Simulations demonstrated that IV Push cefepime resulted in lower PTAs than traditional intermittent infusion among a subset of elevated MICs. #IDTwitter#IJAA https://t.co/fuNkZkybxH
In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria. #JACnews#IDTwitter@BSACandJAC
Dr Nicolau https://t.co/9hHvqr1Amq